$1.16 EPS Expected for PerkinElmer, Inc. (PKI); 3 Analysts Covering DBV Technologies S.A. (DBVT)

PerkinElmer, Inc. (NYSE:PKI) Logo

Analysts expect PerkinElmer, Inc. (NYSE:PKI) to report $1.16 EPS on January, 24.They anticipate $0.19 EPS change or 19.59% from last quarter’s $0.97 EPS. PKI’s profit would be $129.03M giving it 16.36 P/E if the $1.16 EPS is correct. After having $0.90 EPS previously, PerkinElmer, Inc.’s analysts see 28.89% EPS growth. The stock increased 4.30% or $3.13 during the last trading session, reaching $75.92. About 356,234 shares traded. PerkinElmer, Inc. (NYSE:PKI) has risen 18.37% since January 4, 2018 and is uptrending. It has outperformed by 18.37% the S&P500. Some Historical PKI News: 04/04/2018 – Fitch Rates PerkinElmer’s Senior Notes ‘BBB’; Outlook Stable; 26/04/2018 – PerkinElmer Board Declares Quarterly Dividend; 04/04/2018 – Moody’s Rates Perkinelmer’s Senior Unsecured Euro Notes Baa3; 30/04/2018 – PerkinElmer 1Q EPS 23c; 09/05/2018 – PerkinElmer Presenting at UBS Conference May 21; 04/04/2018 – S&PGR Rates PerkinElmer’s Senior Unsecured Notes ‘BBB’; 10/04/2018 – PerkinElmer Appoints James Mock As Chief Financial Officer; 20/03/2018 – BIRAC and PerkinElmer Sign Letter of Intent to Promote India-Led Startups and Innovations; 11/04/2018 – PerkinElmer Expects Proceeds From Sale of the Notes Will Be About EUR297.4 Million; 23/05/2018 – PerkinElmer Acquires Shanghai Spectrum Instruments Co., Ltd

Among 6 analysts covering DBV Technologies (NASDAQ:DBVT), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. DBV Technologies had 8 analyst reports since July 13, 2018 according to SRatingsIntel. Morgan Stanley maintained DBV Technologies S.A. (NASDAQ:DBVT) on Friday, July 13 with “Equal-Weight” rating. The stock of DBV Technologies S.A. (NASDAQ:DBVT) has “Buy” rating given on Friday, November 2 by Bank of America. The rating was maintained by JMP Securities with “Market Outperform” on Thursday, December 20. Morgan Stanley maintained DBV Technologies S.A. (NASDAQ:DBVT) rating on Thursday, December 20. Morgan Stanley has “Equal-Weight” rating and $10 target. On Thursday, December 20 the stock rating was downgraded by Barclays Capital to “Equal-Weight”. Morgan Stanley maintained the stock with “Equal-Weight” rating in Tuesday, September 11 report. The rating was downgraded by Jefferies to “Hold” on Thursday, December 20. See DBV Technologies S.A. (NASDAQ:DBVT) latest ratings:

20/12/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $26 New Target: $10 Maintain
20/12/2018 Broker: Barclays Capital Old Rating: Overweight New Rating: Equal-Weight Old Target: $30 New Target: $8 Downgrade
20/12/2018 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
20/12/2018 Broker: JMP Securities Rating: Market Outperform Old Target: $30 New Target: $20 Maintain
02/11/2018 Broker: Bank of America Old Rating: Buy New Rating: Buy Old Target: $33 New Target: $30 Maintain
14/09/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $35 Initiates Coverage On
11/09/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $28 New Target: $27 Maintain
13/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $27 New Target: $28 Maintain

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company has market cap of $477.81 million. The Company’s lead product candidate is Viaskin Peanut, an immunotherapy product, which is in Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. It currently has negative earnings. The firm is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cowÂ’s milk protein allergy and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of henÂ’s egg allergy; and booster vaccine for Bordatella pertussis.

The stock increased 1.62% or $0.12 during the last trading session, reaching $7.55. About 978,422 shares traded or 51.91% up from the average. DBV Technologies S.A. (NASDAQ:DBVT) has declined 34.24% since January 4, 2018 and is downtrending. It has underperformed by 34.24% the S&P500. Some Historical DBVT News: 14/05/2018 – REG-DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allergy Awareness Week; 08/05/2018 – REG-DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting; 29/05/2018 – DBV Technologies Shows Commitment to the Development of Treatments for Food Allergies at EAACI 2018; 21/03/2018 – DBV TECHNOLOGIES SA DBV.PA – CLOSING OF GLOBAL OFFERING IS EXPECTED TO OCCUR ON MARCH 23, 2018; 28/03/2018 – DBV Tech Closes Above 50-Day Moving Average: Technicals; 21/03/2018 – DBV TECHNOLOGIES SA DBV.PA – MORGAN STANLEY AND GOLDMAN SACHS ARE JOINT LEAD BOOK-RUNNING MANAGERS FOR GLOBAL OFFERING; 12/04/2018 – Bpifrance Participations S.A., Affiliates Report Stake In DBV Technologies; 14/05/2018 – DBV Technologies Partners with FARE to Help Raise Awareness of Food Allergies in Support of the 21st Anniversary of Food Allerg; 16/03/2018 – REG-DBV Technologies Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F; 08/05/2018 – DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting

More notable recent DBV Technologies S.A. (NASDAQ:DBVT) news were published by: Seekingalpha.com which released: “DBV Technologies expands leadership team; shares up 14% premarket – Seeking Alpha” on January 03, 2019, also Fool.com with their article: “Why DBV Technologies Is Being Obliterated Today – The Motley Fool” published on December 20, 2018, Nasdaq.com published: “7 Stocks That Made Big Moves After-hours (TLRY, SPPI, ADMA, DBVT…) – Nasdaq” on December 20, 2018. More interesting news about DBV Technologies S.A. (NASDAQ:DBVT) were released by: Streetinsider.com and their article: “Pre-Open Stock Movers 01/03: (OHRP) (CELG) (DBVT) Higher; (AAPL) (LITE) (BMY) Lower (more…) – StreetInsider.com” published on January 03, 2019 as well as Benzinga.com‘s news article titled: “26 Stocks Moving In Thursday’s Pre-Market Session – Benzinga” with publication date: January 03, 2019.

Investors sentiment increased to 0.94 in Q3 2018. Its up 0.04, from 0.9 in 2018Q2. It improved, as 29 investors sold PerkinElmer, Inc. shares while 117 reduced holdings. 65 funds opened positions while 72 raised stakes. 103.17 million shares or 1.81% less from 105.07 million shares in 2018Q2 were reported. Ing Groep Nv holds 0% or 2,710 shares in its portfolio. Employees Retirement Sys Of Texas, Texas-based fund reported 7,000 shares. Commonwealth Of Pennsylvania Pub School Empls Retrmt has 0.01% invested in PerkinElmer, Inc. (NYSE:PKI) for 9,087 shares. Jefferies Ltd Llc invested in 30,000 shares. Ubs Asset Management Americas holds 0% or 110,602 shares. Bluecrest Capital Management Ltd has invested 0.08% in PerkinElmer, Inc. (NYSE:PKI). State Of Tennessee Treasury Department accumulated 34,097 shares. South Texas Money Management Ltd reported 7,488 shares. Fifth Third Comml Bank stated it has 379 shares or 0% of all its holdings. Moreover, Robecosam Ag has 0.85% invested in PerkinElmer, Inc. (NYSE:PKI) for 225,691 shares. Parsons Capital Management Ri holds 3,000 shares or 0.03% of its portfolio. Alpha Windward Ltd holds 0.02% of its portfolio in PerkinElmer, Inc. (NYSE:PKI) for 375 shares. Nordea Investment Management Ab holds 0% in PerkinElmer, Inc. (NYSE:PKI) or 1,194 shares. Regentatlantic Ltd Co has invested 0.03% in PerkinElmer, Inc. (NYSE:PKI). State Treasurer State Of Michigan reported 373,029 shares.

Among 5 analysts covering PerkinElmer (NYSE:PKI), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. PerkinElmer had 7 analyst reports since August 2, 2018 according to SRatingsIntel. Barclays Capital maintained the shares of PKI in report on Thursday, August 2 with “Underweight” rating. The rating was upgraded by Barclays Capital on Wednesday, September 5 to “Equal-Weight”. Janney Capital downgraded PerkinElmer, Inc. (NYSE:PKI) on Friday, November 2 to “Neutral” rating. The stock of PerkinElmer, Inc. (NYSE:PKI) earned “Overweight” rating by Morgan Stanley on Wednesday, October 10. As per Thursday, August 2, the company rating was maintained by Morgan Stanley. The stock of PerkinElmer, Inc. (NYSE:PKI) has “Neutral” rating given on Thursday, August 2 by Bank of America.

Since August 28, 2018, it had 0 insider buys, and 10 sales for $17.19 million activity. 2,000 shares were sold by LOPARDO NICHOLAS A, worth $174,160 on Friday, November 30. 3,308 shares were sold by Tereau Daniel R, worth $319,487 on Monday, September 24. Another trade for 2,206 shares valued at $184,455 was made by Witz Pascale on Tuesday, November 6. Shares for $14.62M were sold by FRIEL ROBERT F. 5,000 shares were sold by MICHAS ALEXIS P, worth $454,750 on Monday, December 3. $319,088 worth of PerkinElmer, Inc. (NYSE:PKI) was sold by Butters Deborah A. on Monday, October 1. Corbett James also sold $393,870 worth of PerkinElmer, Inc. (NYSE:PKI) on Monday, September 10.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company has market cap of $8.45 billion. The firm operates through two divisions, Discovery and Analytical Solutions and Diagnostics. It has a 67.42 P/E ratio. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its clients to understand the characterization and health of various aspects, including air, water, and soil.

More important recent PerkinElmer, Inc. (NYSE:PKI) news were published by: Seekingalpha.com which released: “PerkinElmer appoints Prahlad Singh as President & COO – Seeking Alpha” on December 10, 2018, also Seekingalpha.com published article titled: “PerkinElmer misses by $0.02, misses on revenue – Seeking Alpha”, Digitaljournal.com published: “PerkinElmer to Present at JP Morgan 37th Annual Healthcare Conference – Press Release – Digital Journal” on December 21, 2018. More interesting news about PerkinElmer, Inc. (NYSE:PKI) was released by: Seekingalpha.com and their article: “PerkinElmer Q3 top line up 22%; earnings down 26%; cash flow ops up 59% – Seeking Alpha” with publication date: October 31, 2018.

PerkinElmer, Inc. (NYSE:PKI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.